Global Memantine Hydrochloride Extended-Release Capsule Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Memantine Hydrochloride Extended-Release Capsule Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Memantine hydrochloride extended-release capsules are a medication used in the treatment of Alzheimer's disease. The active ingredient in these capsules is memantine hydrochloride, which is a type of medication known as an N-methyl-D-aspartate (NMDA) receptor antagonist. Alzheimer's disease is a progressive neurodegenerative disorder that affects memory, thinking, and behavior. It is characterized by the accumulation of a protein called beta-amyloid in the brain, leading to the death of nerve cells and the disruption of normal brain function.
Memantine Hydrochloride Extended-Release Capsule report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Memantine Hydrochloride Extended-Release Capsule market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Home and Hospital are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Memantine Hydrochloride Extended-Release Capsule industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, Memantine Hydrochloride Extended-Release Capsule key companies include Lundbeck, Allergan, Novartis, Lupin Ltd, Huahai Pharmaceutical, Daiichi Sankyo Company Limited, Rottendorf Pharma GmbH, Polygen Pharms and Macleods Pharms, etc. Lundbeck, Allergan, Novartis are top 3 players and held % share in total in 2022.
Memantine Hydrochloride Extended-Release Capsule can be divided into 7mg, 14mg, 21mg and 28mg, etc. 7mg is the mainstream product in the market, accounting for % share globally in 2022.
Memantine Hydrochloride Extended-Release Capsule is widely used in various fields, such as Home, Hospital, Clinic and Others, etc. Home provides greatest supports to the Memantine Hydrochloride Extended-Release Capsule industry development. In 2022, global % share of Memantine Hydrochloride Extended-Release Capsule went into Home filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Memantine Hydrochloride Extended-Release Capsule market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Lundbeck
Allergan
Novartis
Lupin Ltd
Huahai Pharmaceutical
Daiichi Sankyo Company Limited
Rottendorf Pharma GmbH
Polygen Pharms
Macleods Pharms
Amneal Pharms
Apeloa Pharmaceutical
HUMANWELL GROUP
Eisai Co
Ono Pharmaceutical
Slate Run
Easton Bio Pharmaceuticals
Segment by Type
7mg
14mg
21mg
28mg
Others
Home
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Memantine Hydrochloride Extended-Release Capsule market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Memantine Hydrochloride Extended-Release Capsule introduction, etc. Memantine Hydrochloride Extended-Release Capsule Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Memantine Hydrochloride Extended-Release Capsule market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Memantine Hydrochloride Extended-Release Capsule report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Memantine Hydrochloride Extended-Release Capsule market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Home and Hospital are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Memantine Hydrochloride Extended-Release Capsule industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033.
Globally, Memantine Hydrochloride Extended-Release Capsule key companies include Lundbeck, Allergan, Novartis, Lupin Ltd, Huahai Pharmaceutical, Daiichi Sankyo Company Limited, Rottendorf Pharma GmbH, Polygen Pharms and Macleods Pharms, etc. Lundbeck, Allergan, Novartis are top 3 players and held % share in total in 2022.
Memantine Hydrochloride Extended-Release Capsule can be divided into 7mg, 14mg, 21mg and 28mg, etc. 7mg is the mainstream product in the market, accounting for % share globally in 2022.
Memantine Hydrochloride Extended-Release Capsule is widely used in various fields, such as Home, Hospital, Clinic and Others, etc. Home provides greatest supports to the Memantine Hydrochloride Extended-Release Capsule industry development. In 2022, global % share of Memantine Hydrochloride Extended-Release Capsule went into Home filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Memantine Hydrochloride Extended-Release Capsule market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Lundbeck
Allergan
Novartis
Lupin Ltd
Huahai Pharmaceutical
Daiichi Sankyo Company Limited
Rottendorf Pharma GmbH
Polygen Pharms
Macleods Pharms
Amneal Pharms
Apeloa Pharmaceutical
HUMANWELL GROUP
Eisai Co
Ono Pharmaceutical
Slate Run
Easton Bio Pharmaceuticals
Segment by Type
7mg
14mg
21mg
28mg
Others
Segment by Application
Home
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Memantine Hydrochloride Extended-Release Capsule market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Memantine Hydrochloride Extended-Release Capsule introduction, etc. Memantine Hydrochloride Extended-Release Capsule Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Memantine Hydrochloride Extended-Release Capsule market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices